Stock EXEN EXALENZ BIOSCIENCE LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Exalenz Bioscience Ltd

Equities

EXEN

IL0011048688

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 		5-day change 1st Jan Change
- ILa -.--% Intraday chart for Exalenz Bioscience Ltd +1.39% +107.88%
2020 Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others. CI
2020 Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.
CI
Meridian Bioscience : Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
AQ
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.
CI
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System
CI
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
CI
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018
CI
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test
CI
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer
CI
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients
CI
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019
CI
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients
CI
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection
CI
Exalenz Bioscience Plans For Nasdaq IPO
CI
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States
CI
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH
CI
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02
CI
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer
CI
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test
CI
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EXEN Stock
  4. News Exalenz Bioscience Ltd